Delving into the Latest Updates on Arsenious Acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Arsenious Acid and Sodium Chloride, arsenic trihydroxide, arsenous acid

+ [3]

Target-

Mechanism-

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [7]

Active Indication

Acute Promyelocytic LeukemiaBreast CancerColonic Cancer+ [5]

Inactive Indication-

Originator Organization

Harbin Medical University

Active Organization

Harbin Medical University Pharmaceutical Co Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaAsH3O3

InChIKeyGCPXMJHSNVMWNM-UHFFFAOYSA-N

CAS Registry13464-58-9

This is a single center, randomized, double-blinded, controlled, Phase I, small targeted prospective study in healthy male and non-pregnant female subjects, 18 to 49 years old, inclusive, designed to determine the safety, reactogenicity, and immunogenicity of an intramuscular subvirion inactivated monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005) virus vaccine manufactured by Sanofi Pasteur administered at 3.75 mcg per dose given with or without AS03 adjuvant manufactured by GSK. In the study, each subject will receive two doses administered 28 days apart. This study will use a systems biology approach to assess the human early gene and protein signatures expressed at Days 1, 3, 7, and 28 after the first vaccination. The systems data will be integrated with immunogenicity and reactogenicity data to develop a systems model of the human immune response to A/H5N1 vaccine with or without AS03 adjuvant.

Start Date24 May 2012

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Arsenious Acid

Login to view more data

100 Translational Medicine associated with Arsenious Acid

Login to view more data

100 Patents (Medical) associated with Arsenious Acid

Login to view more data

19

Literatures (Medical) associated with Arsenious Acid

05 Jan 2024·Medicine

A case report of acute promyelocytic leukemia with mycosis fungoides

Article

Author: Zhao, Yongqin ; Zhu, Yejing ; Zhang, Fang ; Zhou, Hongjing ; Dong, Shasha

Rationale:Acute promyelocytic leukaemia (APL) is a rare subtype of acute myelogenous leukaemia. With advances in treatment regimens, namely, introduction of all-trans-retinoicacid, outcomes have drastically improved, its side effects should not be ignored. Mycosis fungoides is one of the side effects of all-trans-retinoicacid treatment, but it may also be a clinical manifestation before disease progression. However, it rarely appears and is easily overlooked. This leads to being easily misled during the treatment process, affecting the treatment plan, and resulting in adverse consequences. Therefore, early identification and judgment can not only provide appropriate treatment options, but also prevent and treat further disease progression.Patient concerns:The patient was hospitalized for pancytopaenia. After completing the examination, the patient was finally diagnosed with acute promyelocytic leukaemia (acute myelogenous leukaemia-M3). We administered tretinoin and arsenous acid. Evaluation of the treatment effect on the 7th day after chemotherapy showed that the bone marrow morphology showed complete remission. After the second course of chemotherapy, the patient developed red miliary macular papules, which gradually worsened. After completing relevant inspections, Considering that the cases was complicated with skin mycosis fungoides, the patient was treated with budesonide ointment and methylprednisolone as chemotherapy.Diagnoses:Upon examination, the patient was initially diagnosed with acute promyelocytic leukaemia. Evaluation of the treatment effect on the 7th day after chemotherapy showed that the bone marrow morphology showed complete remission. After the second course of chemotherapy, we discovered the patient was diagnosed with skin mycosis fungoides.Interventions:Systemic chemotherapy is first given when a patient was diagnosed with acute promyelocytic leukaemia. After the patient happened skin mycosis fungoides, We have adjusted the treatment plan and supplemented it with other treatment plans based on the original chemotherapy, After 2 months of treatment, his condition gradually improved.Outcomes:All-trans-retinoicacid in the treatment of APL must be given attention because mycosis fungoides should not only be distinguished from infectious diseases but also be further assessed with regard to disease progression and metastasis.Lessons:Acute promyelocytic leukemia needs to be treated with arsenic trioxide. All-trans-retinoicacid in the treatment of APL must be given attention mycosis fungoides. Early diagnosis can guide accurate treatment, which is of great help in alleviating the pain of patients and improving the cure rate.

14 Jun 2023·bioRxiv : the preprint server for biology

Evidence of Disrupted-in Schizophrenia 1 (DISC1) as an arsenic binding protein and implications regarding its role as a translational activator.

Author: Stewart, Charles E ; Warren, Grant ; Roche, Julien ; Watanabe, Muneaki ; Shin, Juyoung ; Khu, Tung Mei

Disrupted-in-schizophrenia-1 (DISC1) is a scaffold protein that plays a pivotal role in orchestrating signaling pathways involved in neurodevelopment, neural migration, and synaptogenesis. Among those, it has recently been reported that the role DISC1 in the Akt/mTOR pathway can shift from a global translational repressor to a translational activator in response to oxidative stress induced by arsenic. In this study we are providing evidence that DISC1 can directly bind arsenic via a C-terminal cysteine motif (C-X-C-X-C). A series of fluorescence-based binding assays were conducted with a truncated C-terminal domain construct of DISC1 and a of series of single, double, and triple cysteine mutants. We found that arsenous acid, a trivalent arsenic derivative, specifically binds to the C-terminal cysteine motif of DISC1 with low micromolar affinity. All three cysteines of the motif are required for high-affinity binding. Electron microscopy experiments combined with in silico structural predictions revealed that that the C-terminal of DISC1 forms an elongated tetrameric complex. The cysteine motif is consistently predicted to be located within a loop, fully exposed to solvent, providing a simple molecular framework to explain the high-affinity of DISC1 toward arsenous acid. This study sheds light on a novel functional facet of DISC1 as an arsenic binding protein and highlights its potential role as both a sensor and translational modulator within the Akt/mTOR pathway.

01 Dec 2021·Nature NanotechnologyQ1 · MATERIALS SCIENCE

Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects

Q1 · MATERIALS SCIENCE

Article

Author: Shi, Jinan ; Wei, Wei ; Liu, Liyuan ; Ma, Guanghui ; Yue, Hua ; Yu, Siyao ; Wang, Shuang ; Gao, Zirui ; Hu, Yuxing ; Ma, Ding ; Zhou, Wu ; Li, Yuhua ; Wang, Changlong ; Li, Feng ; Zhao, Chaochao ; Zhang, Wei ; He, Yanjie ; Li, Hui

Trivalent arsenic (As^III) is an effective agent for treating patients with acute promyelocytic leukaemia, but its ionic nature leads to several major limitations like low effective concentrations in leukaemia cells and substantial off-target cytotoxicity, which limits its general application to other types of leukaemia. Here, building from our clinical discovery that cancerous cells from patients with different leukaemia forms featured stable and strong expression of CD71, we designed a ferritin-based As nanomedicine, As@Fn, that bound to leukaemia cells with very high affinity, and efficiently delivered cytotoxic As^III into a large diversity of leukaemia cell lines and patient cells. Moreover, As@Fn exerted strong anti-leukaemia effects in diverse cell-line-derived xenograft models, as well as in a patient-derived xenograft model, in which it consistently outperformed the gold standard, showing its potential as a precision treatment for a variety of leukaemias.

100 Deals associated with Arsenious Acid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Arsenious Acid	L01	DB04456

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Promyelocytic Leukemia	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Breast Cancer	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Colonic Cancer	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Liver Cancer	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Lung Cancer	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Multiple Myeloma	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Pancreatic Cancer	CN	Harbin Medical University Pharmaceutical Co Ltd.	-
Uterine Cervical Cancer	CN	Harbin Medical University Pharmaceutical Co Ltd.	-